Carcinoid Tumor Syndrome Management Market

Carcinoid Tumor Syndrome Management Market


Carcinoid Tumor Syndrome Management Market: Global Industry Analysis 2018-2022 and Opportunity Assessment 2023-2033

A recent market study published by FMI on Carcinoid Tumor Syndrome Management offers a global industry analysis for 2018-2022 and opportunity assessment for 2023-2033. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Market Segmentation

By Organ Affected:
  • Small Intestine
  • Lungs
  • Rectum
  • Appendix
  • Stomach
  • Liver
  • Others
By Therapy Type:
  • Chemotherapy
  • Biological Therapy
  • Radio Therapy
By Drug:
  • Octreotide
  • Telotristat Etiprate
  • Lanreotide
By Route of Administration:
  • Oral
  • Injectable
By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA
Report Chapters

Executive Summary

The executive summary of the Carcinoid Tumor Syndrome Management Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Vehicle Radar Test System.

Chapter 01 - Market Overview

Readers can find the detailed segmentation and definition of the Carcinoid Tumor Syndrome Management Market in this chapter, which will help to understand basic information about Vehicle Radar Test System. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of Carcinoid Tumor Syndrome Management Market report.

Chapter 02 - Market Background

This chapter includes detailed analysis of the By Organ Affected processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.

Chapter 03 - Global Carcinoid Tumor Syndrome Management Market Demand Analysis 2018-2022 and Forecast, 2023-2033

The chapter include historical market value (XX) analysis (2018-2022) and current and future market value (US$ 1774.38 Million) and volume (10.9%) projections (2023-2033). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.

Chapter 04 - Global Carcinoid Tumor Syndrome Management Market - Pricing Analysis

Based on By Organ Affected, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.

Chapter 05 - Global Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033, By Organ Affected

Based on By Organ Affected, Carcinoid Tumor Syndrome Management Market is segmented into Small Intestine, Lungs, Rectum, Appendix, Stomach, Liver, Others. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Organ Affected.

Chapter 06 - Global Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033, By Therapy Type

Based on By Therapy Type, Carcinoid Tumor Syndrome Management Market is segmented into Chemotherapy, Biological Therapy, Radio Therapy. This section also offers market attractiveness analysis based on By Therapy Type. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Therapy Type.

Chapter 07 - Global Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033, By Drug

Based on By Drug, Carcinoid Tumor Syndrome Management Market is segmented into Octreotide, Telotristat Etiprate, Lanreotide. This section also offers market attractiveness analysis based on By Drug. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Drug.

Chapter 08 - Global Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033, By Route of Administration

Based on By Route of Administration, Carcinoid Tumor Syndrome Management Market is segmented into Oral, Injectable. This section also offers market attractiveness analysis based on By Route of Administration. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Route of Administration.

Chapter 09 - Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033, By Region

Based on By Region, Carcinoid Tumor Syndrome Management Market is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania and MEA. This section also offers market attractiveness analysis based on By Region. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Region.

Chapter 10 - North America Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of the Vehicle Radar Test System in the North American region, along with a country-wise assessment that includes the US and Canada. Readers can also find regional trends, regulations, and market growth based on different segment and countries in the North America region.

Chapter 11 - Latin America Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the Latin America region, along with a country-wise assessment that includes the Brazil, Mexico, Chile, Argentina, Peru and Rest of Latin America. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Carcinoid Tumor Syndrome Management Market in the Latin America region.

Chapter 12 - Europe Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the European region, along with a country-wise assessment that includes the Germany, Italy, France, U.K., Spain, Russia, Nordic, Benelux and Rest of Europe. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Carcinoid Tumor Syndrome Management Market in the regional market.

Chapter 13 - East Asia Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the East Asia region, along with a country-wise assessment that includes the China, Japan, and South Korea. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Carcinoid Tumor Syndrome Management Market in the regional market.

Chapter 14 - South Asia Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the South Asia region, along with a country-wise assessment that includes the India, Indonesia, Malaysia, Thailand, and Rest of South Asia. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Carcinoid Tumor Syndrome Management Market in the regional market.

Chapter 15 - Middle East and Africa Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter includes a detailed analysis of the growth of Vehicle Radar Test System in the MEA region, along with a country-wise assessment that includes the GCC Countries, South Africa, North Africa, Turkey and Rest of MEA. Readers can find detailed information about several factors, such as the pricing analysis and regional trends, which are impacting growth of the Carcinoid Tumor Syndrome Management Market in the regional market.

Chapter 16 - Key Countries Carcinoid Tumor Syndrome Management Market Analysis 2018-2022 and Forecast 2023-2033

This chapter offers insights into how the Carcinoid Tumor Syndrome Management Market is expected to grow in major countries globally.

Chapter 17 - Market Structure Analysis- Global Assessment

This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.

Chapter 18 - Competition Deep Dive (Tentative List)

This chapter includes company overview, By Organ Affected portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Biopharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Amgen Inc., Entrinsic Health Solutions, Inc., Endo Pharmaceuticals Inc., Sirtex SIR-Spheres Pty Ltd, BTG International Ltd.

Chapter 19 - Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Vehicle Radar Test System report.

Chapter 20 - Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on Carcinoid Tumor Syndrome Management Market.


1. Executive Summary | Carcinoid Tumor Syndrome Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
 3.1.1. Drivers
 3.1.2. Restraints
 3.1.3. Opportunity
 3.1.4. Trends
3.2. Scenario Forecast
 3.2.1. Demand in Optimistic Scenario
 3.2.2. Demand in Likely Scenario
 3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
 3.6.1. By Key Regions
 3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
 4.2.1. Y-o-Y Growth Trend Analysis
 4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Organ Affected
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Organ Affected, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Organ Affected, 2023 to 2033
 5.3.1. Small Intestine
 5.3.2. Lungs
 5.3.3. Rectum
 5.3.4. Appendix
 5.3.5. Stomach
 5.3.6. Liver
 5.3.7. Others
5.4. Y-o-Y Growth Trend Analysis By Organ Affected, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Organ Affected, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
 6.3.1. Chemotherapy
 6.3.2. Biological Therapy
 6.3.3. Radiotherapy
6.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Drug , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug , 2023 to 2033
 7.3.1. Octreotide
 7.3.2. Telotristat Etiprate
 7.3.3. Lanreotide
7.4. Y-o-Y Growth Trend Analysis By Drug , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Drug , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
 8.3.1. Oral
 8.3.2. Injectable
8.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
 9.3.1. Retail Pharmacies
 9.3.2. Hospital Pharmacies
 9.3.3. Online Pharmacies
9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
 10.3.1. North America
 10.3.2. Latin America
 10.3.3. Europe
 10.3.4. South Asia
 10.3.5. East Asia
 10.3.6. Oceania
 10.3.7. MEA
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 11.2.1. By Country
 11.2.1.1. USA
 11.2.1.2. Canada
 11.2.2. By Organ Affected
 11.2.3. By Therapy Type
 11.2.4. By Drug
 11.2.5. By Route of Administration
 11.2.6. By Distribution Channel
11.3. Market Attractiveness Analysis
 11.3.1. By Country
 11.3.2. By Organ Affected
 11.3.3. By Therapy Type
 11.3.4. By Drug
 11.3.5. By Route of Administration
 11.3.6. By Distribution Channel
11.4. Key Takeaways
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 12.2.1. By Country
 12.2.1.1. Brazil
 12.2.1.2. Mexico
 12.2.1.3. Rest of Latin America
 12.2.2. By Organ Affected
 12.2.3. By Therapy Type
 12.2.4. By Drug
 12.2.5. By Route of Administration
 12.2.6. By Distribution Channel
12.3. Market Attractiveness Analysis
 12.3.1. By Country
 12.3.2. By Organ Affected
 12.3.3. By Therapy Type
 12.3.4. By Drug
 12.3.5. By Route of Administration
 12.3.6. By Distribution Channel
12.4. Key Takeaways
13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 13.2.1. By Country
 13.2.1.1. Germany
 13.2.1.2. United kingdom
 13.2.1.3. France
 13.2.1.4. Spain
 13.2.1.5. Italy
 13.2.1.6. Rest of Europe
 13.2.2. By Organ Affected
 13.2.3. By Therapy Type
 13.2.4. By Drug
 13.2.5. By Route of Administration
 13.2.6. By Distribution Channel
13.3. Market Attractiveness Analysis
 13.3.1. By Country
 13.3.2. By Organ Affected
 13.3.3. By Therapy Type
 13.3.4. By Drug
 13.3.5. By Route of Administration
 13.3.6. By Distribution Channel
13.4. Key Takeaways
14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 14.2.1. By Country
 14.2.1.1. India
 14.2.1.2. Malaysia
 14.2.1.3. Singapore
 14.2.1.4. Thailand
 14.2.1.5. Rest of South Asia
 14.2.2. By Organ Affected
 14.2.3. By Therapy Type
 14.2.4. By Drug
 14.2.5. By Route of Administration
 14.2.6. By Distribution Channel
14.3. Market Attractiveness Analysis
 14.3.1. By Country
 14.3.2. By Organ Affected
 14.3.3. By Therapy Type
 14.3.4. By Drug
 14.3.5. By Route of Administration
 14.3.6. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 15.2.1. By Country
 15.2.1.1. China
 15.2.1.2. Japan
 15.2.1.3. South Korea
 15.2.2. By Organ Affected
 15.2.3. By Therapy Type
 15.2.4. By Drug
 15.2.5. By Route of Administration
 15.2.6. By Distribution Channel
15.3. Market Attractiveness Analysis
 15.3.1. By Country
 15.3.2. By Organ Affected
 15.3.3. By Therapy Type
 15.3.4. By Drug
 15.3.5. By Route of Administration
 15.3.6. By Distribution Channel
15.4. Key Takeaways
16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 16.2.1. By Country
 16.2.1.1. Australia
 16.2.1.2. New Zealand
 16.2.2. By Organ Affected
 16.2.3. By Therapy Type
 16.2.4. By Drug
 16.2.5. By Route of Administration
 16.2.6. By Distribution Channel
16.3. Market Attractiveness Analysis
 16.3.1. By Country
 16.3.2. By Organ Affected
 16.3.3. By Therapy Type
 16.3.4. By Drug
 16.3.5. By Route of Administration
 16.3.6. By Distribution Channel
16.4. Key Takeaways
17. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
 17.2.1. By Country
 17.2.1.1. GCC Countries
 17.2.1.2. South Africa
 17.2.1.3. Israel
 17.2.1.4. Rest of MEA
 17.2.2. By Organ Affected
 17.2.3. By Therapy Type
 17.2.4. By Drug
 17.2.5. By Route of Administration
 17.2.6. By Distribution Channel
17.3. Market Attractiveness Analysis
 17.3.1. By Country
 17.3.2. By Organ Affected
 17.3.3. By Therapy Type
 17.3.4. By Drug
 17.3.5. By Route of Administration
 17.3.6. By Distribution Channel
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. USA
 18.1.1. Pricing Analysis
 18.1.2. Market Share Analysis, 2022
 18.1.2.1. By Organ Affected
 18.1.2.2. By Therapy Type
 18.1.2.3. By Drug
 18.1.2.4. By Route of Administration
 18.1.2.5. By Distribution Channel
18.2. Canada
 18.2.1. Pricing Analysis
 18.2.2. Market Share Analysis, 2022
 18.2.2.1. By Organ Affected
 18.2.2.2. By Therapy Type
 18.2.2.3. By Drug
 18.2.2.4. By Route of Administration
 18.2.2.5. By Distribution Channel
18.3. Brazil
 18.3.1. Pricing Analysis
 18.3.2. Market Share Analysis, 2022
 18.3.2.1. By Organ Affected
 18.3.2.2. By Therapy Type
 18.3.2.3. By Drug
 18.3.2.4. By Route of Administration
 18.3.2.5. By Distribution Channel
18.4. Mexico
 18.4.1. Pricing Analysis
 18.4.2. Market Share Analysis, 2022
 18.4.2.1. By Organ Affected
 18.4.2.2. By Therapy Type
 18.4.2.3. By Drug
 18.4.2.4. By Route of Administration
 18.4.2.5. By Distribution Channel
18.5. Germany
 18.5.1. Pricing Analysis
 18.5.2. Market Share Analysis, 2022
 18.5.2.1. By Organ Affected
 18.5.2.2. By Therapy Type
 18.5.2.3. By Drug
 18.5.2.4. By Route of Administration
 18.5.2.5. By Distribution Channel
18.6. United kingdom
 18.6.1. Pricing Analysis
 18.6.2. Market Share Analysis, 2022
 18.6.2.1. By Organ Affected
 18.6.2.2. By Therapy Type
 18.6.2.3. By Drug
 18.6.2.4. By Route of Administration
 18.6.2.5. By Distribution Channel
18.7. France
 18.7.1. Pricing Analysis
 18.7.2. Market Share Analysis, 2022
 18.7.2.1. By Organ Affected
 18.7.2.2. By Therapy Type
 18.7.2.3. By Drug
 18.7.2.4. By Route of Administration
 18.7.2.5. By Distribution Channel
18.8. Spain
 18.8.1. Pricing Analysis
 18.8.2. Market Share Analysis, 2022
 18.8.2.1. By Organ Affected
 18.8.2.2. By Therapy Type
 18.8.2.3. By Drug
 18.8.2.4. By Route of Administration
 18.8.2.5. By Distribution Channel
18.9. Italy
 18.9.1. Pricing Analysis
 18.9.2. Market Share Analysis, 2022
 18.9.2.1. By Organ Affected
 18.9.2.2. By Therapy Type
 18.9.2.3. By Drug
 18.9.2.4. By Route of Administration
 18.9.2.5. By Distribution Channel
18.10. India
 18.10.1. Pricing Analysis
 18.10.2. Market Share Analysis, 2022
 18.10.2.1. By Organ Affected
 18.10.2.2. By Therapy Type
 18.10.2.3. By Drug
 18.10.2.4. By Route of Administration
 18.10.2.5. By Distribution Channel
18.11. Malaysia
 18.11.1. Pricing Analysis
 18.11.2. Market Share Analysis, 2022
 18.11.2.1. By Organ Affected
 18.11.2.2. By Therapy Type
 18.11.2.3. By Drug
 18.11.2.4. By Route of Administration
 18.11.2.5. By Distribution Channel
18.12. Singapore
 18.12.1. Pricing Analysis
 18.12.2. Market Share Analysis, 2022
 18.12.2.1. By Organ Affected
 18.12.2.2. By Therapy Type
 18.12.2.3. By Drug
 18.12.2.4. By Route of Administration
 18.12.2.5. By Distribution Channel
18.13. Thailand
 18.13.1. Pricing Analysis
 18.13.2. Market Share Analysis, 2022
 18.13.2.1. By Organ Affected
 18.13.2.2. By Therapy Type
 18.13.2.3. By Drug
 18.13.2.4. By Route of Administration
 18.13.2.5. By Distribution Channel
18.14. China
 18.14.1. Pricing Analysis
 18.14.2. Market Share Analysis, 2022
 18.14.2.1. By Organ Affected
 18.14.2.2. By Therapy Type
 18.14.2.3. By Drug
 18.14.2.4. By Route of Administration
 18.14.2.5. By Distribution Channel
18.15. Japan
 18.15.1. Pricing Analysis
 18.15.2. Market Share Analysis, 2022
 18.15.2.1. By Organ Affected
 18.15.2.2. By Therapy Type
 18.15.2.3. By Drug
 18.15.2.4. By Route of Administration
 18.15.2.5. By Distribution Channel
18.16. South Korea
 18.16.1. Pricing Analysis
 18.16.2. Market Share Analysis, 2022
 18.16.2.1. By Organ Affected
 18.16.2.2. By Therapy Type
 18.16.2.3. By Drug
 18.16.2.4. By Route of Administration
 18.16.2.5. By Distribution Channel
18.17. Australia
 18.17.1. Pricing Analysis
 18.17.2. Market Share Analysis, 2022
 18.17.2.1. By Organ Affected
 18.17.2.2. By Therapy Type
 18.17.2.3. By Drug
 18.17.2.4. By Route of Administration
 18.17.2.5. By Distribution Channel
18.18. New Zealand
 18.18.1. Pricing Analysis
 18.18.2. Market Share Analysis, 2022
 18.18.2.1. By Organ Affected
 18.18.2.2. By Therapy Type
 18.18.2.3. By Drug
 18.18.2.4. By Route of Administration
 18.18.2.5. By Distribution Channel
18.19. GCC Countries
 18.19.1. Pricing Analysis
 18.19.2. Market Share Analysis, 2022
 18.19.2.1. By Organ Affected
 18.19.2.2. By Therapy Type
 18.19.2.3. By Drug
 18.19.2.4. By Route of Administration
 18.19.2.5. By Distribution Channel
18.20. South Africa
 18.20.1. Pricing Analysis
 18.20.2. Market Share Analysis, 2022
 18.20.2.1. By Organ Affected
 18.20.2.2. By Therapy Type
 18.20.2.3. By Drug
 18.20.2.4. By Route of Administration
 18.20.2.5. By Distribution Channel
18.21. Israel
 18.21.1. Pricing Analysis
 18.21.2. Market Share Analysis, 2022
 18.21.2.1. By Organ Affected
 18.21.2.2. By Therapy Type
 18.21.2.3. By Drug
 18.21.2.4. By Route of Administration
 18.21.2.5. By Distribution Channel
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
 19.3.1. By Regional
 19.3.2. By Organ Affected
 19.3.3. By Therapy Type
 19.3.4. By Drug
 19.3.5. By Route of Administration
 19.3.6. By Distribution Channel
20. Competition Analysis
20.1. Competition Deep Dive
 20.1.1. Novartis AG
 20.1.1.1. Overview
 20.1.1.2. Product Portfolio
 20.1.1.3. Profitability by Market Segments
 20.1.1.4. Sales Footprint
 20.1.1.5. Strategy Overview
  20.1.1.5.1. Marketing Strategy
 20.1.2. Teva Pharmaceutical Industries Ltd.
 20.1.2.1. Overview
 20.1.2.2. Product Portfolio
 20.1.2.3. Profitability by Market Segments
 20.1.2.4. Sales Footprint
 20.1.2.5. Strategy Overview
  20.1.2.5.1. Marketing Strategy
 20.1.3. Mylan N.V.
 20.1.3.1. Overview
 20.1.3.2. Product Portfolio
 20.1.3.3. Profitability by Market Segments
 20.1.3.4. Sales Footprint
 20.1.3.5. Strategy Overview
  20.1.3.5.1. Marketing Strategy
 20.1.4. Ipsen Biopharmaceuticals, Inc
 20.1.4.1. Overview
 20.1.4.2. Product Portfolio
 20.1.4.3. Profitability by Market Segments
 20.1.4.4. Sales Footprint
 20.1.4.5. Strategy Overview
  20.1.4.5.1. Marketing Strategy
 20.1.5. Sun Pharmaceutical Industries Ltd
 20.1.5.1. Overview
 20.1.5.2. Product Portfolio
 20.1.5.3. Profitability by Market Segments
 20.1.5.4. Sales Footprint
 20.1.5.5. Strategy Overview
  20.1.5.5.1. Marketing Strategy
 20.1.6. Amgen Inc.
 20.1.6.1. Overview
 20.1.6.2. Product Portfolio
 20.1.6.3. Profitability by Market Segments
 20.1.6.4. Sales Footprint
 20.1.6.5. Strategy Overview
  20.1.6.5.1. Marketing Strategy
 20.1.7. Entrinsic Health Solutions, Inc.
 20.1.7.1. Overview
 20.1.7.2. Product Portfolio
 20.1.7.3. Profitability by Market Segments
 20.1.7.4. Sales Footprint
 20.1.7.5. Strategy Overview
  20.1.7.5.1. Marketing Strategy
 20.1.8. Endo Pharmaceuticals Inc.
 20.1.8.1. Overview
 20.1.8.2. Product Portfolio
 20.1.8.3. Profitability by Market Segments
 20.1.8.4. Sales Footprint
 20.1.8.5. Strategy Overview
  20.1.8.5.1. Marketing Strategy
 20.1.9. Sirtex SIR-Spheres Pty Ltd
 20.1.9.1. Overview
 20.1.9.2. Product Portfolio
 20.1.9.3. Profitability by Market Segments
 20.1.9.4. Sales Footprint
 20.1.9.5. Strategy Overview
  20.1.9.5.1. Marketing Strategy
 20.1.10. BTG International Ltd
 20.1.10.1. Overview
 20.1.10.2. Product Portfolio
 20.1.10.3. Profitability by Market Segments
 20.1.10.4. Sales Footprint
 20.1.10.5. Strategy Overview
  20.1.10.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings